Business
Appointment of Chief Financial Officer
Appointment of Chief Financial Officer.
About this update from Hvivo Plc
[{"type":"text","content":"\n \nRNS Number : 1045Q Venn Life Sciences Holdings PLC 15 June 2015 \n\n \nVenn Life Sciences Holdings Plc\n(\"Venn\" or the \"Company\" or the \"Group\")\n \nAppointment of Chief Financial Officer\n \nOn 12 May 2015, Venn Life Sciences (AIM: VENN), a growing Clinical Research Organisation providing clinical trial management and resourcing solutions to pharmaceutical, biotechnology and medical device clients, announced the appointment of Jonathan Hartshorn as Chief Financial Officer with effect from 15th June 2015. \n \nThe Company is pleased to confirm that Jonathan will begin his duties in that role today. \n \nThe Company reaffirms that save as disclosed in the announcement of 12 May 2015, there are no other disclosures required in relation to paragraph (g) of Schedule 2 of the AIM Rules for Companies.\n \nEnquiries:\n \n\n\n\n\nVenn Life Sciences Holdings Plc\n\n\nwww.vennlifesciences.com\n\n\n\n\nTony Richardson, Chief Executive Officer\n\n\nTel: +353 154 99 341\n\n\n\n\nOrla Mc Guinness, Marketing Manager\n \n\n\nTel: +33 676 93 11 78\n\n\n\n\nZeus Capital (Nominated Adviser and Broker)\n\n\n\n\n\n\n\nRoss Andrews/Andrew Jones\n\n\nTel: 0161 831 1512\n\n\n\n\nAlex Davies\n\n\nTel: 020 7533 7727\n\n\n\n\n\n\n\n\n\n\n\n\nWalbrook PR Ltd\n\n\nTel: +44 (0)20 7933 8780 or [email protected]\n\n\n\n\nPaul McManus\n\n\nMob: +44 (0)7980 541 893\n\n\n\n\nLianne Cawthorne\n\n\nMob: +44 (0)7584 391 303\n\n\n\n\n \n \n \n \nAbout Venn Life Sciences Limited:\nVenn Life Sciences is a Clinical Research Organisation providing clinical trial management and resourcing solutions to pharmaceutical, biotechnology and medical device organisations. With dedicated operations in France, Germany, the Netherlands, the UK, Ireland and Europe wide representation - Venn specialises in rapid deployment and management of multisite projects. Venn recently established an innovation division - Innovenn - focused primarily on breakthrough development opportunities in Skin Science.\n \n \n \n\nThis information is provided by RNSThe company news service from the London Stock Exchange END MSCBIGDLCUBBGUS\n ","length":5063,"tagName":"div"}]